Advertisement

Ano-uro-genital mucosal melanoma UK national guidelines

      Highlights

      • Mucosal melanomas of ano-uro-genital structures are rare malignancies with poor prognoses.
      • Owing to their rarity, there is limited evidence in the literature to guide clinical decision making.
      • We provide a summary of the evidence and recommendations for the management of AUG melanoma.

      Abstract

      Ano-uro-genital (AUG) mucosal melanomas are rare cancers associated with poor outcomes and limited evidence-based management. The United Kingdom AUG mucosal melanoma guideline development group used an evidence-based systematic approach to make recommendations regarding the diagnosis, treatment and surveillance of patients diagnosed with AUG mucosal melanomas. The guidelines were sent for international peer review, and are accredited by The National Institute for Health and Clinical Excellence (NICE). A summary of the key recommendations is presented. The full documents are available on the Melanoma Focus website.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bishop K.D.
        • Olszewski A.J.
        Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis.
        Int J Cancer. 2014; 134: 2961-2971
        • Falch C.
        • Stojadinovic A.
        • Hann-von-Weyhern C.
        • Protic M.
        • Nissan A.
        • Faries M.B.
        • et al.
        Anorectal malignant melanoma: extensive 45-year review and proposal for a novel staging classification.
        J Am Coll Surg. 2013; 217: 324-335
        • Zhang S.
        • Gao F.
        • Wan D.
        Effect of misdiagnosis on the prognosis of anorectal malignant melanoma.
        J Cancer Res Clin Oncol. 2010; 136: 1401-1405
        • Chen L.
        • Xiong Y.
        • Wang H.
        • Liang L.
        • Shang H.
        • Yan X.
        Malignant melanoma of the vagina: a case report and review of the literature.
        Oncol Lett. 2014; 8: 1585-1588
        • Kelly P.
        • Zagars G.K.
        • Cormier J.N.
        • Ross M.I.
        • Guadagnolo B.A.
        Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: a 20-year experience.
        Cancer. 2011; 117: 4747-4755
        • Nigogosyan G.
        • Delapava S.
        • Pickren J.W.
        Melanoblasts in vaginal mucosa. Origin for primary malignant melanoma.
        Cancer. 1964; 17: 912-913
        • Hu D.N.
        • Yu G.P.
        • McCormick S.A.
        Population-based incidence of vulvar and vaginal melanoma in various races and ethnic groups with comparisons to other site-specific melanomas.
        Melanoma Res. 2010; 20: 153-158
        • Gokaslan H.
        • Sismanoglu A.
        • Pekin T.
        • Kaya H.
        • Ceyhan N.
        Primary malignant melanoma of the vagina: a case report and review of the current treatment options.
        Eur J Obstet Gynecol Reprod Biol. 2005; 121: 243-248
        • Sanchez-Ortiz R.
        • Huang S.F.
        • Tamboli P.
        • Prieto V.G.
        • Hester G.
        • Pettaway C.A.
        Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience.
        J Urol. 2005; 173: 1958-1965
        • Bechara G.R.
        • Schwindt A.B.
        • Ornellas A.A.
        • Silva D.E.
        • Lott F.M.
        • Campos F.S.
        Penile primary melanoma: analysis of 6 patients treated at Brazilian National Cancer Institute in the last eight years.
        Int Braz J Urol. 2013; 39: 823-831
        • Ascierto P.A.
        • Flaherty K.
        • Goff S.
        Emerging strategies in systemic therapy for the treatment of melanoma.
        Am Soc Clin Oncol Educ Book. 2018; 38: 751-758
        • Ponti G.
        • Manfredini M.
        • Greco S.
        • Pellacani G.
        • Depenni R.
        • Tomasi A.
        • et al.
        BRAF, NRAS and C-KIT advanced melanoma: clinico-pathological features, targeted-therapy strategies and survival.
        Anticancer Res. 2017; 37: 7043-7048
        • Rabbie R.
        • Ferguson P.
        • Molina-Aguilar C.
        • Adams D.J.
        • Robles-Espinoza C.D.
        Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities.
        J Pathol. 2019; 247: 539-551